Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,429.00GBp
12:10pm EDT
Change (% chg)

28.00 (+0.52%)
Prev Close
5,401.00
Open
5,416.00
Day's High
5,519.00
Day's Low
5,408.00
Volume
2,146,581
Avg. Vol
2,401,579
52-wk High
5,585.07
52-wk Low
3,994.50

Select another date:

AstraZeneca escapes lawsuit over clinical drug trial

A federal judge has dismissed claims against AstraZeneca PLC by a Massachusetts lawyer who claimed he was misled into participating in a clinical trial of a cholesterol drug that failed to treat his kidney disease.

GSK's new pharma head to join in September after AstraZeneca tussle

LONDON GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca.

UPDATE 1-GSK's new pharma head to join in September after AstraZeneca tussle

LONDON, June 19 GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca.

GSK to get new pharma head in Sept, after AstraZeneca tussle

LONDON, June 19 GlaxoSmithKline said on Monday it had reached an agreement for Luke Miels to start as its new head of pharmaceuticals on Sept. 4, following a drawn-out dispute over his contract with former employer AstraZeneca. (Reporting by Ben Hirschler; Editing by Kate Kelland)

New test may turn AZ's Lynparza into precision drug for prostate cancer

LONDON Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca's drug Lynparza into a precision medicine for prostate cancer.

New test may turn AZ's Lynparza into precision drug for prostate cancer

LONDON, June 19 Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca's drug Lynparza into a precision medicine for prostate cancer.

BRIEF-Astrazeneca presents new data underpinning safety profile and real-world cv outcomes of Farxiga at ADA 2017

* Astrazeneca presents new data underpinning safety profile and real-world cv outcomes of farxiga at ada 2017

BRIEF-Astrazeneca to present scientific advances in cardiovascular, metabolic diseases

* Astrazeneca to present scientific advances in cardiovascular and metabolic diseases at 2017 ADA scientific sessions Source text for Eikon: Further company coverage:

AstraZeneca sells migraine drug for up to $302 million

LONDON AstraZeneca continued its program of divesting old medicines on Wednesday with the sale for up to $302 million of migraine drug Zomig to Germany's Grunenthal.

AstraZeneca sells migraine drug for up to $302 mln

LONDON, June 7 AstraZeneca continued its programme of divesting old medicines on Wednesday with the sale for up to $302 million of migraine drug Zomig to Germany's Grunenthal.

Select another date:

More From Around the Web